PMC:7281546 / 54948-57109 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T333","span":{"begin":5,"end":13},"obj":"Body_part"},{"id":"T334","span":{"begin":160,"end":164},"obj":"Body_part"},{"id":"T335","span":{"begin":276,"end":280},"obj":"Body_part"},{"id":"T336","span":{"begin":288,"end":309},"obj":"Body_part"},{"id":"T337","span":{"begin":311,"end":313},"obj":"Body_part"},{"id":"T338","span":{"begin":383,"end":390},"obj":"Body_part"},{"id":"T339","span":{"begin":493,"end":497},"obj":"Body_part"},{"id":"T340","span":{"begin":629,"end":631},"obj":"Body_part"},{"id":"T341","span":{"begin":699,"end":704},"obj":"Body_part"},{"id":"T342","span":{"begin":1778,"end":1781},"obj":"Body_part"},{"id":"T343","span":{"begin":1896,"end":1899},"obj":"Body_part"}],"attributes":[{"id":"A333","pred":"fma_id","subj":"T333","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A334","pred":"fma_id","subj":"T334","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A335","pred":"fma_id","subj":"T335","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A336","pred":"fma_id","subj":"T336","obj":"http://purl.org/sig/ont/fma/fma63842"},{"id":"A337","pred":"fma_id","subj":"T337","obj":"http://purl.org/sig/ont/fma/fma63842"},{"id":"A338","pred":"fma_id","subj":"T338","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A339","pred":"fma_id","subj":"T339","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A340","pred":"fma_id","subj":"T340","obj":"http://purl.org/sig/ont/fma/fma63842"},{"id":"A341","pred":"fma_id","subj":"T341","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A342","pred":"fma_id","subj":"T342","obj":"http://purl.org/sig/ont/fma/fma67095"},{"id":"A343","pred":"fma_id","subj":"T343","obj":"http://purl.org/sig/ont/fma/fma67095"}],"text":"PEDV Proteins The Biological Processes Involved References\nS (S1 and S2) receptor binding and subsequent membrane fusion; replication cycle and propagation; cell apoptosis induction [48,49,50,128]\nN viral replication, transcription, and assembly; extension of S-phase of cell cycle; endoplasmic reticulum (ER) stress formation; innate immunity antagonist; interaction with host protein NPM1 [44,56,57,129]\nM virion assembly and virus budding; induction of PEDV neutralizing antibodies; cell growth retardation in S-phase; IFN antagonist with unknown mechanism [62,63,64,65]\nE virus packaging and budding; stimulation of ER stress and activation of NF-κB pathway [66,67]\nORF3 detention of cells at S-phase; facilitating vesicle formation; promoting PEDV replication [69,70]\nnsp1 type I IFNs and type III IFN antagonists; inducing the degradation of CBP; suppression of phosphorylation and degradation of IκBα, as well as p65 nuclear translocation; blocking nuclear translocation of IRF1 [65,78,130]\nnsp2 Unknown\nnsp3,4,6 nsp3, 4, and 6 are all involved in viral replication process; nsp3 also acts as a viral deubiquitinase (DUB) that deubiquitinates RIG-I and STING and negatively regulates type I IFN signaling [80,94,99]\nnsp5 3CLpro; processing replicase polyprotein during virus replication; blocking host innate immune responses by cleavage of NF-κB essential modulator (NEMO) [99]\nnsp7–10 Nsp7 is an IFN antagonist; nsp8 inhibits type III IFN response; nsp9 is involved in nucleic acid binding; nsp10 enhances the inhibitory effect of nsp16 on IFN-β production. [65,131,132,133]\nnsp12 encoding a RdRp; viral replication [134]\nnsp13 a NTPase/helicase that is essential for viral replication [111]\nnsp14 N-7-MTase; catalyzing N7-methylation of Gppp-RNA to form a cap-0 structure; 3′-5′ exoribonuclease activity involves in a replicative mismatch repair system during RNA synthesis; IFN antagonist [42,65,112,113,119,133]\nnsp15 EndoU; IFN antagonist; inhibition of the type I IFN and the type III IFN responses [114,115,116,135]\nnsp16 2′-O-MTase that catalyzes methylation of the 5’ cap; IFN antagonist [112,123,124,125,126,132]"}

LitCovid-PD-UBERON

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T9","span":{"begin":252,"end":261},"obj":"Body_part"}],"attributes":[{"id":"A9","pred":"uberon_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/UBERON_2000106"}],"text":"PEDV Proteins The Biological Processes Involved References\nS (S1 and S2) receptor binding and subsequent membrane fusion; replication cycle and propagation; cell apoptosis induction [48,49,50,128]\nN viral replication, transcription, and assembly; extension of S-phase of cell cycle; endoplasmic reticulum (ER) stress formation; innate immunity antagonist; interaction with host protein NPM1 [44,56,57,129]\nM virion assembly and virus budding; induction of PEDV neutralizing antibodies; cell growth retardation in S-phase; IFN antagonist with unknown mechanism [62,63,64,65]\nE virus packaging and budding; stimulation of ER stress and activation of NF-κB pathway [66,67]\nORF3 detention of cells at S-phase; facilitating vesicle formation; promoting PEDV replication [69,70]\nnsp1 type I IFNs and type III IFN antagonists; inducing the degradation of CBP; suppression of phosphorylation and degradation of IκBα, as well as p65 nuclear translocation; blocking nuclear translocation of IRF1 [65,78,130]\nnsp2 Unknown\nnsp3,4,6 nsp3, 4, and 6 are all involved in viral replication process; nsp3 also acts as a viral deubiquitinase (DUB) that deubiquitinates RIG-I and STING and negatively regulates type I IFN signaling [80,94,99]\nnsp5 3CLpro; processing replicase polyprotein during virus replication; blocking host innate immune responses by cleavage of NF-κB essential modulator (NEMO) [99]\nnsp7–10 Nsp7 is an IFN antagonist; nsp8 inhibits type III IFN response; nsp9 is involved in nucleic acid binding; nsp10 enhances the inhibitory effect of nsp16 on IFN-β production. [65,131,132,133]\nnsp12 encoding a RdRp; viral replication [134]\nnsp13 a NTPase/helicase that is essential for viral replication [111]\nnsp14 N-7-MTase; catalyzing N7-methylation of Gppp-RNA to form a cap-0 structure; 3′-5′ exoribonuclease activity involves in a replicative mismatch repair system during RNA synthesis; IFN antagonist [42,65,112,113,119,133]\nnsp15 EndoU; IFN antagonist; inhibition of the type I IFN and the type III IFN responses [114,115,116,135]\nnsp16 2′-O-MTase that catalyzes methylation of the 5’ cap; IFN antagonist [112,123,124,125,126,132]"}

LitCovid-PD-MONDO

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T120","span":{"begin":861,"end":864},"obj":"Disease"}],"attributes":[{"id":"A120","pred":"mondo_id","subj":"T120","obj":"http://purl.obolibrary.org/obo/MONDO_0010565"}],"text":"PEDV Proteins The Biological Processes Involved References\nS (S1 and S2) receptor binding and subsequent membrane fusion; replication cycle and propagation; cell apoptosis induction [48,49,50,128]\nN viral replication, transcription, and assembly; extension of S-phase of cell cycle; endoplasmic reticulum (ER) stress formation; innate immunity antagonist; interaction with host protein NPM1 [44,56,57,129]\nM virion assembly and virus budding; induction of PEDV neutralizing antibodies; cell growth retardation in S-phase; IFN antagonist with unknown mechanism [62,63,64,65]\nE virus packaging and budding; stimulation of ER stress and activation of NF-κB pathway [66,67]\nORF3 detention of cells at S-phase; facilitating vesicle formation; promoting PEDV replication [69,70]\nnsp1 type I IFNs and type III IFN antagonists; inducing the degradation of CBP; suppression of phosphorylation and degradation of IκBα, as well as p65 nuclear translocation; blocking nuclear translocation of IRF1 [65,78,130]\nnsp2 Unknown\nnsp3,4,6 nsp3, 4, and 6 are all involved in viral replication process; nsp3 also acts as a viral deubiquitinase (DUB) that deubiquitinates RIG-I and STING and negatively regulates type I IFN signaling [80,94,99]\nnsp5 3CLpro; processing replicase polyprotein during virus replication; blocking host innate immune responses by cleavage of NF-κB essential modulator (NEMO) [99]\nnsp7–10 Nsp7 is an IFN antagonist; nsp8 inhibits type III IFN response; nsp9 is involved in nucleic acid binding; nsp10 enhances the inhibitory effect of nsp16 on IFN-β production. [65,131,132,133]\nnsp12 encoding a RdRp; viral replication [134]\nnsp13 a NTPase/helicase that is essential for viral replication [111]\nnsp14 N-7-MTase; catalyzing N7-methylation of Gppp-RNA to form a cap-0 structure; 3′-5′ exoribonuclease activity involves in a replicative mismatch repair system during RNA synthesis; IFN antagonist [42,65,112,113,119,133]\nnsp15 EndoU; IFN antagonist; inhibition of the type I IFN and the type III IFN responses [114,115,116,135]\nnsp16 2′-O-MTase that catalyzes methylation of the 5’ cap; IFN antagonist [112,123,124,125,126,132]"}

LitCovid-PD-CLO

LitCovid-PD-CHEBI

LitCovid-PD-HP

{"project":"LitCovid-PD-HP","denotations":[{"id":"T30","span":{"begin":498,"end":516},"obj":"Phenotype"}],"attributes":[{"id":"A30","pred":"hp_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/HP_0001510"}],"text":"PEDV Proteins The Biological Processes Involved References\nS (S1 and S2) receptor binding and subsequent membrane fusion; replication cycle and propagation; cell apoptosis induction [48,49,50,128]\nN viral replication, transcription, and assembly; extension of S-phase of cell cycle; endoplasmic reticulum (ER) stress formation; innate immunity antagonist; interaction with host protein NPM1 [44,56,57,129]\nM virion assembly and virus budding; induction of PEDV neutralizing antibodies; cell growth retardation in S-phase; IFN antagonist with unknown mechanism [62,63,64,65]\nE virus packaging and budding; stimulation of ER stress and activation of NF-κB pathway [66,67]\nORF3 detention of cells at S-phase; facilitating vesicle formation; promoting PEDV replication [69,70]\nnsp1 type I IFNs and type III IFN antagonists; inducing the degradation of CBP; suppression of phosphorylation and degradation of IκBα, as well as p65 nuclear translocation; blocking nuclear translocation of IRF1 [65,78,130]\nnsp2 Unknown\nnsp3,4,6 nsp3, 4, and 6 are all involved in viral replication process; nsp3 also acts as a viral deubiquitinase (DUB) that deubiquitinates RIG-I and STING and negatively regulates type I IFN signaling [80,94,99]\nnsp5 3CLpro; processing replicase polyprotein during virus replication; blocking host innate immune responses by cleavage of NF-κB essential modulator (NEMO) [99]\nnsp7–10 Nsp7 is an IFN antagonist; nsp8 inhibits type III IFN response; nsp9 is involved in nucleic acid binding; nsp10 enhances the inhibitory effect of nsp16 on IFN-β production. [65,131,132,133]\nnsp12 encoding a RdRp; viral replication [134]\nnsp13 a NTPase/helicase that is essential for viral replication [111]\nnsp14 N-7-MTase; catalyzing N7-methylation of Gppp-RNA to form a cap-0 structure; 3′-5′ exoribonuclease activity involves in a replicative mismatch repair system during RNA synthesis; IFN antagonist [42,65,112,113,119,133]\nnsp15 EndoU; IFN antagonist; inhibition of the type I IFN and the type III IFN responses [114,115,116,135]\nnsp16 2′-O-MTase that catalyzes methylation of the 5’ cap; IFN antagonist [112,123,124,125,126,132]"}

LitCovid-PD-GO-BP

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T420","span":{"begin":0,"end":60},"obj":"Sentence"},{"id":"T421","span":{"begin":61,"end":200},"obj":"Sentence"},{"id":"T422","span":{"begin":201,"end":411},"obj":"Sentence"},{"id":"T423","span":{"begin":412,"end":581},"obj":"Sentence"},{"id":"T424","span":{"begin":582,"end":679},"obj":"Sentence"},{"id":"T425","span":{"begin":680,"end":784},"obj":"Sentence"},{"id":"T426","span":{"begin":785,"end":1011},"obj":"Sentence"},{"id":"T427","span":{"begin":1012,"end":1025},"obj":"Sentence"},{"id":"T428","span":{"begin":1026,"end":1239},"obj":"Sentence"},{"id":"T429","span":{"begin":1240,"end":1404},"obj":"Sentence"},{"id":"T430","span":{"begin":1405,"end":1604},"obj":"Sentence"},{"id":"T431","span":{"begin":1605,"end":1653},"obj":"Sentence"},{"id":"T432","span":{"begin":1654,"end":1725},"obj":"Sentence"},{"id":"T433","span":{"begin":1726,"end":1950},"obj":"Sentence"},{"id":"T434","span":{"begin":1951,"end":2059},"obj":"Sentence"},{"id":"T435","span":{"begin":2060,"end":2161},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"PEDV Proteins The Biological Processes Involved References\nS (S1 and S2) receptor binding and subsequent membrane fusion; replication cycle and propagation; cell apoptosis induction [48,49,50,128]\nN viral replication, transcription, and assembly; extension of S-phase of cell cycle; endoplasmic reticulum (ER) stress formation; innate immunity antagonist; interaction with host protein NPM1 [44,56,57,129]\nM virion assembly and virus budding; induction of PEDV neutralizing antibodies; cell growth retardation in S-phase; IFN antagonist with unknown mechanism [62,63,64,65]\nE virus packaging and budding; stimulation of ER stress and activation of NF-κB pathway [66,67]\nORF3 detention of cells at S-phase; facilitating vesicle formation; promoting PEDV replication [69,70]\nnsp1 type I IFNs and type III IFN antagonists; inducing the degradation of CBP; suppression of phosphorylation and degradation of IκBα, as well as p65 nuclear translocation; blocking nuclear translocation of IRF1 [65,78,130]\nnsp2 Unknown\nnsp3,4,6 nsp3, 4, and 6 are all involved in viral replication process; nsp3 also acts as a viral deubiquitinase (DUB) that deubiquitinates RIG-I and STING and negatively regulates type I IFN signaling [80,94,99]\nnsp5 3CLpro; processing replicase polyprotein during virus replication; blocking host innate immune responses by cleavage of NF-κB essential modulator (NEMO) [99]\nnsp7–10 Nsp7 is an IFN antagonist; nsp8 inhibits type III IFN response; nsp9 is involved in nucleic acid binding; nsp10 enhances the inhibitory effect of nsp16 on IFN-β production. [65,131,132,133]\nnsp12 encoding a RdRp; viral replication [134]\nnsp13 a NTPase/helicase that is essential for viral replication [111]\nnsp14 N-7-MTase; catalyzing N7-methylation of Gppp-RNA to form a cap-0 structure; 3′-5′ exoribonuclease activity involves in a replicative mismatch repair system during RNA synthesis; IFN antagonist [42,65,112,113,119,133]\nnsp15 EndoU; IFN antagonist; inhibition of the type I IFN and the type III IFN responses [114,115,116,135]\nnsp16 2′-O-MTase that catalyzes methylation of the 5’ cap; IFN antagonist [112,123,124,125,126,132]"}

LitCovid-PubTator

PMC:7281546 / 54948-57109 JSONTXT

Annnotations TAB JSON ListView MergeView

PMC:7281546 / 54948-57109 JSON TXT